Drug Profile
Research programme: targeted nanoparticle therapeutics - Pfizer
Alternative Names: Accurins®; BIND 267; BIND-510; KSP inhibitor accurin; PLK1 inhibitor accurin; PSMA-targeted vincristine - PfizerLatest Information Update: 28 Dec 2019
Price :
$50
*
At a glance
- Originator BIND Biosciences
- Developer BIND Therapeutics; Pfizer
- Class
- Mechanism of Action KIF11 protein inhibitors; Polo-like kinase 1 inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Haematological malignancies; Infections; Solid tumours
- Discontinued Cardiovascular disorders; Inflammation
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for preclinical development in Infections in USA
- 28 Feb 2019 No recent reports of development identified for preclinical development in Cancer in USA
- 28 Feb 2019 No recent reports of development identified for preclinical development in Haematological-malignancies in USA